Pipeline

invoX has performed research activities across a spectrum of product classes and indications validating the versatility of the Softhaler® platform. We focus our internal current pipeline for the treatments of Chronic Obstructive Pulmonary Disease (COPD), Asthma, Pulmonary arterial hypertension (PAH), Cystic Fibrosis (CF) and Idiopathic Pulmonary Fibrosis (IPF).

Further work is underway to expand the platform’s drug delivery capabilities in order to widen the spectrum of molecules that can be delivered.

For example, we are conducting research in delivering various biological molecules with Softhaler®, including peptide, nucleic acid, enzyme, and antibodies. Here we are open to Partnering.

Our pipeline selection process

We have robust internal R&D processes which help us effectively identify high potential future products for application with Softhaler® platform. Our phased development process spans from early research to late development with milestone deliverables at each phase ensuring robust control of quality, risk and value on investment. We implement the latest CMC digital software and development tools, for instance in silico models to forecast in vivo performance, to design and develop our products to the highest quality for the patient.